Gravity Analytica

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

PSNL 12.19.2024

Full Press Release SEC Filings Our PSNL Tweets

About Gravity Analytica

Recent Filings

FREMONT, Calif.--(BUSINESS WIRE)--Dec. 19, 2024--Personalis, Inc.(NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outsidethe United StatesandCanada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen therapy (INT), being jointly developed by Merck and Moderna.

Merck has agreed to purchase$50 millionofPersonaliscommon stock in a private placement at a price of$3.56per share, which was the last reported closing price of Personalis’ common stock as reported on The Nasdaq Global Market onDecember 18, 2024. Following the closing, Merck will own approximately 14 million shares ofPersonaliscommon stock, representing an approximately 16.5 percent beneficial ownership interest inPersonalis.

“Individualized therapies have the potential to transform cancer care,” saidChris Hall, CEO ofPersonalis. “A key focus forPersonalishas been supporting Merck and Moderna in this important program and we are thrilled to extend the collaboration potentially through to treatment of cancer patients on a routine basis.”

Merck and Moderna have utilized Personalis’ industry-leading tumor-profiling platform since the inception of the V940/mRNA-4157 clinical development program.

“We are grateful for the long-term relationship with Merck and Moderna. Additionally, this investment reinforces our strategic role in Merck’s precision oncology efforts,” added Hall.

AboutPersonalis, Inc.

AtPersonalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.Personalisis based inFremont, California. To learn more, visitwww.personalis.comand connect with us onLinkedInandX, formerly known as Twitter.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are “forward-looking statements” within the meaning ofU.S.securities laws, including statements relating to the expected closing of Merck’s common stock investment inPersonalis, Moderna’s continued utilization of Personalis’ ImmunoID NeXT Platform and technology as a part of the V940/mRNA-4157 clinical development program, the term of the collaboration betweenPersonalisand Moderna for multiple years, the potential for individualized therapies to transform cancer care, and the potential extension of the collaboration with Merck and Moderna to treatment of cancer patients on a routine basis. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the expected benefits of INTs and Personalis’ collaboration with Moderna, the continuation or expansion of Moderna’s INT clinical trial portfolio, the potential for Merck and Moderna to receive FDA approval for INTs, potential future market acceptance of INTs into routine clinical practice, the expected benefits of Merck’s purchase of shares of Personalis’ common stock and continuation of Personalis’ strategic role in Merck’s precision oncology efforts. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year endedDecember 31, 2023, filed with theSecurities and Exchange Commission(SEC) onFebruary 28, 2024, as updated by Personalis’ Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2024, filed with theSEConMay 8, 2024, Quarterly Report on Form 10-Q for the quarter endedJune 30, 2024, filed with theSEConAugust 7, 2024, and Quarterly Report on Form 10-Q for the quarter endedSeptember 30, 2024, filed with theSEConNovember 6, 2024. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof.Personalisundertakes no duty to update this information unless required by law.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241219301298/en/

Investors:Caroline Cornerinvestors@personalis.com415-202-5678

Media ContactPatrick Schmidtpr@personalis.com630-290-2787

Source:Personalis, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

PSNL 12.19.2024

About Gravity Analytica

Recent News

Recent Filings